Forest Laboratories Sank To New Low for Year Wednesday -
USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040 -
Forest Laboratories Finishes At Multi-Year Low -
Forest Laboratories (FRX) NewsBite - Forest Laboratories Falls on Drug Study Results -
Forest Laboratories Slides In Pre-Market On Phase III Study Results On COPD Drug -
FRX touches 50-day moving average at 31.52 -
www.companiesandmarkets.com: Forest Laboratories, Inc - SWOT Analysis -
Forest Laboratories Drops To 3-Week Low -
FRX touches 200-day moving average at 36.72 -
Lupin signs marketing agreement with Forest Laboratories -
India's Lupin in multi-year marketing agreement with Forest Laboratories -
Forest Laboratories announces positive Phase III data for Alzheimer's drug -
Forest Laboratories reports growth in Q1 revenue -
Forest Laboratories (FRX) NewsBite - FRX Price Target Cut -
Forest Labs 1Q EPS 79c, including charges of 8c a share -